In ®Entresto we trust

Area of Science:

• Cardio-Oncology
• Pharmacology
• Heart Failure Management

Background:

• Heart failure with reduced ejection fraction (HFrEF) is a significant concern in cancer patients.
• Cancer therapies, such as anthracyclines, can induce cardiotoxicity leading to HFrEF.
• Patients with cancer therapy-induced HFrEF were excluded from pivotal Sacubitril/Valsartan trials.

Purpose of the Study:

• To evaluate the efficacy and safety of Sacubitril/Valsartan (S/V) in patients with HFrEF caused by cancer therapy.
• To establish the value of S/V in this specific, vulnerable patient subgroup.

Main Methods:

• Retrospective analysis of a small cohort of cancer patients with HFrEF.
• Patients primarily included women with breast cancer treated with anthracyclines.
• Assessment of S/V treatment effects on cardiac function and clinical outcomes.

Main Results:

• Limited data suggest Sacubitril/Valsartan shows encouraging effects in this population.
• Results appear consistent with prior studies on S/V in broader HFrEF populations.
• No major adverse events related to S/V were highlighted in this small group.

Conclusions:

• Sacubitril/Valsartan may be a valuable treatment option for cancer patients with therapy-induced HFrEF.
• Further prospective studies are warranted to confirm these preliminary findings.
• This research supports the consideration of S/V in cardio-oncology practice.